SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Under to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 1, 1998
Commission File Number: 1-10013
LarsonoDavis Incorporated
(Exact Name of Registrant as Specified in its Charter)
Nevada 87-0429944
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
1681 West 820 North
Provo, Utah 84601
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including Area Code:
(801) 375-0177
(Former name, former address, and formal fiscal year, if changed since
last report)
ITEM 5. OTHER EVENTS
Effective May 1, 1998, Larson Davis Incorporated (the "Company") appointed
Sir Colin Dollery and Mr. Stanley Friedman as non-executive directors of the
Company.
Sir Colin Dollery, 67, currently serves as a senior consultant to the
research and development group at SmithKline Beecham PLC. Prior to this, he
served as Chairman of Clinical and Biopharmaceutical Consultancy Ltd., served as
a non-executive director of Life Sciences International PLC, and has been
employed by Merck & Company as well as by Zeneca Pharmaceuticals PLC in various
senior advisory roles, reporting to the Board of Directors. A former Professor
and Chairman of the Department of Clinical Pharmacology at the Royal
Postgraduate Medical School, he holds the title of Professor Emeritus at the
University of London and holds a number of advanced degrees.
Mr. Stanley Friedman, 70, has had extensive experience in high technology
corporations. He served at ITT Corporation for 15 years, retiring as a
Corporate Vice-President and Group Executive. Previous executive positions
included Vice-President and Division General Manager with Lockheed Electronics,
a division of Lockheed Aircraft Corporation, as well as management positions
with RCA Corp. An electrical engineering graduate of Worcester Polytechnic
Institute, he holds an advanced engineering degree from Purdue University in
addition to being a Sloan Fellow at Stanford University. He is currently a
director of Spaulding Composites, Inc., a manufacturer of industrial materials.
As a result of the above appointments, the prior non-executive directors,
Gerard Seelig and William Hosker, relinquished their board positions affective
April 30.
Each of the new directors received an option to acquire 30,000 shares of
common stock of the Company in conjunction with their appointment. These
options vest, and are exercisable, with respect to 15,000 shares on May 1, 1999,
and 15,000 shares on May 1, 2000. The option exercise price is $2.9375 per
share, reflecting the trading price for the common stock as reported by Nasdaq
at the time of the grant.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange of 1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Dated: May 22, 1998 LARSONoDAVIS INCORPORATED
By /s/ Craig Allen
Craig Allen
(Principal Financial and
Accounting Officer)
